Updated
Reviewed
Appendices
Appendix A. Key to Acronyms
Abbreviation | Full Name |
---|---|
3TC | Lamivudine |
5-FU | 5-fluorouracil |
9vHPV | 9-valent human papillomavirus [vaccine] |
ABLC | amphotericin B lipid complex |
BCA | bichloroacetic acid |
BCG | Bacille Calmette-Guérin [vaccine] |
DEET | N,N-diethyl-meta-toluamide |
DTaP | diphtheria, tetanus, and acellular pertussis [vaccine] |
EFV | efavirenz |
FTC | emtricitabine |
HBIG | hepatitis B immune globulin |
HepA | hepatitis A [vaccine] |
HepB | hepatitis B [vaccine] |
IIV | inactivated influenza vaccine |
IPV | inactivated polio vaccine |
IVIG | intravenous immune globulin |
LAIV | live attenuated influenza vaccine |
L-AmB | liposomal amphotericin B |
MCV | meningococcal conjugate vaccine |
MenACWY | meningococcal strains A, C, W, Y [vaccine] |
MMR | measles, mumps, and rubella [vaccine] |
MMRV | measles, mumps, rubella, and varicella [vaccine] |
NVP | nevirapine |
PCV | pneumococcal conjugate vaccine |
PCV13 | 13-valent pneumococcal conjugate vaccine |
PCV7 | 7-valent pneumococcal conjugate vaccine |
Peg-IFN-α | pegylated interferon-alpha |
PPSV | pneumococcal polysaccharide vaccine |
PPSV23 | pneumococcal polysaccharide vaccine (23-valent) |
RV | rotavirus vaccine |
RZV | recombinant zoster vaccine |
TCA | trichloroacetic acid |
Td | tetanus and diphtheria [vaccine] |
Tdap | tetanus and diphtheria toxoids and acellular pertussis [vaccine] |
TMP-SMX | trimethoprim-sulfamethoxazole |
TPOXX | tecovirimat |
YFV | yellow fever vaccine |
ZVL | zoster vaccine live |
Acronym | Definition |
---|---|
A-a | alveolar-arterial |
AAFP | American Academy of Family Physicians |
AAP | American Academy of Pediatrics |
ACIP | Advisory Committee on Immunization Practices |
ACOG | American College of Obstetricians and Gynecologists |
AFB | acid-fast bacteria |
AFP | alpha-fetoprotein |
AIN | anal intraepithelial neoplasia |
ALT | alanine aminotransferase |
ANC | absolute neutrophil count |
ARDS | acute respiratory distress syndrome |
ARN | acute retinal necrosis |
ART | antiretroviral therapy |
ARV | antiretroviral |
ASCCP | American Society for Colposcopy and Cervical Pathology |
ASC-H | atypical squamous cells—cannot exclude a high-grade intraepithelial lesion |
ASC-US | atypical squamous cells of undetermined significance |
BID | twice daily |
BP | blood pressure |
BSA | body surface area |
BUN | blood urea nitrogen |
cART | combination antiretroviral therapy |
CBC | complete blood count |
CD4 | CD4 T lymphocyte |
CDC | Centers for Disease Control and Prevention |
CF | complement fixation |
CFU | colony-forming unit |
CI | confidence interval |
CIN | cervical intraepithelial neoplasia |
CIN1 | cervical intraepithelial neoplasia-1 |
CMV | cytomegalovirus |
CNS | central nervous system |
Cr | creatinine |
CrCl | creatinine clearance |
CSF | cerebrospinal fluid |
CT | computerized tomography |
CYP450 | cytochrome P450 |
DFA | direct fluorescent antibody |
DOT | directly observed therapy |
DST | drug susceptibility test |
EIA | enzyme immunoassay |
EKG | electrocardiogram |
ESRD | end stage renal disease |
EVR | early virologic response |
FDA | U.S. Food and Drug Administration |
FTA-ABS | fluorescent treponemal antibody absorption |
G6PD | glucose-6-phosphate dehydrogenase |
GI | gastrointestinal |
H | hemagglutinin |
HAB | hepatitis B (rDNA) |
HAI | hemagglutination inhibition |
HAV | hepatitis A virus |
HBc | hepatitis B core antigen |
HBeAg | hepatitis B e antigen |
HBsAg | hepatitis B surface antigen |
HBV | hepatitis B virus |
HCC | hepatocellular carcinoma |
HCV | hepatitis C virus |
HEU | HIV-exposed but uninfected |
HHS | U.S. Department of Health and Human Services |
HHV-8 | human herpesvirus-8 |
Hib | Haemophilus influenzae type b |
HIV-1 | human immunodeficiency virus 1 |
HIVMA | HIV Medicine Association |
HPV | human papillomavirus |
HRA | high-resolution anoscopy |
HSIL | high-grade squamous intraepithelial lesion |
HSV | herpes simplex virus |
HSV-1 | herpes simplex virus type 1 |
HSV-2 | herpes simplex virus type 2 |
HZ | herpes zoster |
ICP | intracranial pressure |
IDSA | Infectious Diseases Society of America |
IFN | interferon |
IFN-α | interferon-alfa |
IFN-γ | interferon-gamma |
IgG | immunoglobulin G |
IgM | immunoglobulin M |
IGRA | interferon-gamma release assay |
IL28B | interleukin-28 |
IM | intramuscular |
IND | investigational new drug |
IPD | invasive pneumococcal disease |
IRIS | immune reconstitution inflammatory syndrome |
IU | international unit |
IV | intravenous |
JCV | JC (John Cunningham) virus |
JORRP | juvenile-onset recurrent respiratory papillomatosis |
KS | Kaposi sarcoma |
KSHV | Kaposi sarcoma–associated herpesvirus |
KS-IRIS | Kaposi sarcoma–associated immune reconstitution inflammatory syndrome |
LAM | lipoarabinomannan |
LEEP | loop electrosurgical excision procedure |
LFT | liver function test |
LIP | lymphocytic interstitial pneumonitis |
LSIL | low-grade squamous intraepithelial lesion |
LTBI | latent tuberculosis infection |
LV-PVA | low-viscosity polyvinyl alcohol |
MAC | Mycobacterium avium complex |
MDR | multidrug-resistant |
MDR-TB | multidrug-resistant tuberculosis |
MRI | magnetic resonance imaging |
MRSA | methicillin-resistant Staphylococcus aureus |
MSM | men who have sex with men |
MTCT | mother-to-child transmission |
mtLSU | mitochondrial large subunit |
N | neuraminidase |
NAAT | nucleic acid amplification test |
NCCN | National Comprehensive Cancer Network |
NCCR | non-coding control region |
NIH | National Institutes of Health |
NNRTI | non-nucleoside reverse transcriptase inhibitor |
NRTI | nucleoside reverse transcriptase inhibitor |
NSAID | nonsteroidal anti-inflammatory drug |
NTM | nontuberculous mycobacteria |
OAR | Office of AIDS Research |
OARAC | Office of AIDS Research Advisory Council |
OI | opportunistic infection |
OPC | oropharyngeal candidiasis |
OR | odds ratio |
PaO2 | partial pressure of oxygen |
PART | presumptive anti-relapse therapy |
PCP | Pneumocystis jirovecii pneumonia |
PCR | polymerase chain reaction |
PDH | progressive disseminated histoplasmosis |
PI | protease inhibitor |
PICO | Population of interest, Intervention being considered, Comparison intervention or condition, and Outcomes of interest |
PIDS | Pediatric Infectious Disease Society |
PI-IBS | post-infection irritable bowel syndrome |
PK | pharmacokinetic |
PML | progressive multifocal leukoencephalopathy |
PMTCT | prevention of mother-to-child transmission |
QFT | QuantiFERON-TB |
QID | four times daily |
QTc | QT corrected for heart rate |
RDT | rapid diagnostic test |
RIDT | rapid influenza diagnostic test |
RPR | rapid plasma reagin |
RR | relative risk; risk ratio |
RT | reverse transcription |
RT-PCR | reverse transcription–polymerase chain reaction |
RVR | rapid virological response |
SAF | sodium acetate-acetic acid-formalin |
SC | squamous cell |
SIL | squamous intraepithelial lesion |
SJS | Stevens-Johnson Syndrome |
SMR | sexual maturity rating |
SQ | subcutaneous |
STD | sexually transmitted disease |
SVR | sustained virologic response |
TB | tuberculosis |
TBM | tuberculous meningitis |
TDM | therapeutic drug monitoring |
TE | Toxoplasma encephalitis |
TID | three times daily |
TP-PA | T. pallidum particle agglutination |
TST | tuberculin skin test |
ULN | upper limit of normal |
USPHS | U.S. Public Health Service |
VAERS | Vaccine Adverse Event Reporting System |
VaIN | vaginal intraepithelial neoplasia |
Var | varicella |
VDRL | Venereal Disease Research Laboratory |
VIN | vulvar intraepithelial neoplasia |
VZV | varicella-zoster virus |
WBC | white blood cell |
WHO | World Health Organization |
XDR | extensively drug-resistant |
XDR-TB | extensively drug-resistant tuberculosis |
YMDD | tyrosine-methionine-aspartate-aspartate |
Acronym | Name |
---|---|
PACTG | Pediatric AIDS Clinical Trials Group |
Download Guidelines
- Section Only PDF (74.69 KB)
- Full Guideline PDF (5.23 MB)
- Recommendations Only PDF (368.53 KB)
- Tables Only PDF (992.82 KB)
- Dosing Tables PDF (553.3 KB)